Virginia G. Kaklamani
Division of Hematology/Oncology
Northwestern University
676 North St. Clair Street
Suite 850
USA
Name/email consistency: high
- Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Kaklamani, V.G., Siziopikou, K., Scholtens, D., Lacouture, M., Gordon, J., Uthe, R., Meservey, C., Hansen, N., Khan, S.A., Jeruss, J.S., Bethke, K., Cianfrocca, M., Rosen, S., Von Roenn, J., Wayne, J., Parimi, V., Jovanovic, B., Gradishar, W. Breast Cancer Res. Treat. (2011)
- Global experience with ixabepilone in breast cancer. Kaklamani, V.G., Xu, B.H., Gomez, H.L. Expert. Rev. Anticancer. Ther (2011)
- A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX. Kaklamani, V. Expert Rev. Mol. Diagn. (2006)
- Role of TGF-beta in cancer and the potential for therapy and prevention. Kaklamani, V.G., Pasche, B. Expert. Rev. Anticancer. Ther (2004)
- Role of capecitabine (Xeloda) in breast cancer. Kaklamani, V.G., Gradishar, W.J. Expert. Rev. Anticancer. Ther (2003)